“…Penafuerte et al reported that TGF-β antagonist inhibited tumor growth and angiogenesis by inducing STAT1 activation [ 48 ]. Besides, studies have found a close association between STAT1 expression and PD-L1 expression in triple-negative breast cancer and ovarian cancer [ 49 , 50 ]. Overexpression of STAT1 in breast cancer cells could recruit the infiltration of myeloid-derived suppressor cells and inhibit the cytotoxicity of the T cells [ 51 ].…”